Global Terbinafine Hydrochloride Drug

Terbinafine Hydrochloride Drug Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Topical, Oral), Duration of therapy (Fingernail onychomycosis, Toenail onychomycosis), Patient (Adult Dose, Pediatric Dose) Players and Region - Global Market Outlook to 2026

Terbinafine Hydrochloride Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Terbinafine Hydrochloride Drug Market?

Terbinafine is used to treat certain types of fungal infections (for example, of the fingernail or toenail). It works by stopping the growth of fungus. This medication belongs to a class of drugs known as antifungals. The use of these drugs is as an antifungal medication that fights infections caused by fungus. Terbinafine tablets are used to treat infections caused by a fungus that affect the fingernails or toenails. Terbinafine oral granules are used to treat a fungal infection of scalp hair follicles in children who are at least 4 years old.

The market study is being classified, by Application (Athlete's Foot, Jock Itch, Ringworm and Others) and major geographies with country level break-up.

Novartis (Switzerland), GSK (United Kingdom), TEVA (Israel), Dr. Reddy's Laboratories(India), CIPLA LTD (India), Quimica Sintetica S.A. (Spain), Dipharma (United States), InvaGen Pharmaceuticals (United States), Breckenridge Pharmaceutical(United States) and Harris Pharmaceutical(United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Glenmark (India), Orchid Healthcare (India), APOTEX (Canada) and Jilin Wantong Group (China).

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Terbinafine Hydrochloride Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Terbinafine Hydrochloride Drug market by Type, Application and Region.

On the basis of geography, the market of Terbinafine Hydrochloride Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing sports and event worldwide
  • The rise in the prevalence of skin infection such as ringworm


Restraints
  • The adverse effect of the Terbinafine Hydrochloride Drug

Opportunities
  • The increasing number of cases of dermatological related diseases drives the tinea corporis drugs to demand in the market

Challenges
  • Use of homemade therapy as a substitute





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Terbinafine Hydrochloride Drug Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Application
  • Athlete's Foot
  • Jock Itch
  • Ringworm
  • Others
By Route of Administration
  • Topical
  • Oral

By Duration of therapy
  • Fingernail onychomycosis
  • Toenail onychomycosis

By Patient
  • Adult Dose
  • Pediatric Dose

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing sports and event worldwide
      • 3.2.2. The rise in the prevalence of skin infection such as ringworm
    • 3.3. Market Challenges
      • 3.3.1. Use of homemade therapy as a substitute
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Terbinafine Hydrochloride Drug, by Application, Route of Administration, Duration of therapy, Patient and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Terbinafine Hydrochloride Drug (Value)
      • 5.2.1. Global Terbinafine Hydrochloride Drug by: Application (Value)
        • 5.2.1.1. Athlete's Foot
        • 5.2.1.2. Jock Itch
        • 5.2.1.3. Ringworm
        • 5.2.1.4. Others
      • 5.2.2. Global Terbinafine Hydrochloride Drug by: Route of Administration (Value)
        • 5.2.2.1. Topical
        • 5.2.2.2. Oral
      • 5.2.3. Global Terbinafine Hydrochloride Drug by: Duration of therapy (Value)
        • 5.2.3.1. Fingernail onychomycosis
        • 5.2.3.2. Toenail onychomycosis
      • 5.2.4. Global Terbinafine Hydrochloride Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Terbinafine Hydrochloride Drug (Volume)
      • 5.3.1. Global Terbinafine Hydrochloride Drug by: Application (Volume)
        • 5.3.1.1. Athlete's Foot
        • 5.3.1.2. Jock Itch
        • 5.3.1.3. Ringworm
        • 5.3.1.4. Others
      • 5.3.2. Global Terbinafine Hydrochloride Drug by: Route of Administration (Volume)
        • 5.3.2.1. Topical
        • 5.3.2.2. Oral
      • 5.3.3. Global Terbinafine Hydrochloride Drug by: Duration of therapy (Volume)
        • 5.3.3.1. Fingernail onychomycosis
        • 5.3.3.2. Toenail onychomycosis
      • 5.3.4. Global Terbinafine Hydrochloride Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Terbinafine Hydrochloride Drug (Price)
  • 6. Terbinafine Hydrochloride Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GSK (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. TEVA (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dr. Reddy's Laboratories(India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CIPLA LTD (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Quimica Sintetica S.A. (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dipharma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. InvaGen Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Breckenridge Pharmaceutical(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Harris Pharmaceutical(United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Terbinafine Hydrochloride Drug Sale, by Application, Route of Administration, Duration of therapy, Patient and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Terbinafine Hydrochloride Drug (Value)
      • 7.2.1. Global Terbinafine Hydrochloride Drug by: Application (Value)
        • 7.2.1.1. Athlete's Foot
        • 7.2.1.2. Jock Itch
        • 7.2.1.3. Ringworm
        • 7.2.1.4. Others
      • 7.2.2. Global Terbinafine Hydrochloride Drug by: Route of Administration (Value)
        • 7.2.2.1. Topical
        • 7.2.2.2. Oral
      • 7.2.3. Global Terbinafine Hydrochloride Drug by: Duration of therapy (Value)
        • 7.2.3.1. Fingernail onychomycosis
        • 7.2.3.2. Toenail onychomycosis
      • 7.2.4. Global Terbinafine Hydrochloride Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Terbinafine Hydrochloride Drug (Volume)
      • 7.3.1. Global Terbinafine Hydrochloride Drug by: Application (Volume)
        • 7.3.1.1. Athlete's Foot
        • 7.3.1.2. Jock Itch
        • 7.3.1.3. Ringworm
        • 7.3.1.4. Others
      • 7.3.2. Global Terbinafine Hydrochloride Drug by: Route of Administration (Volume)
        • 7.3.2.1. Topical
        • 7.3.2.2. Oral
      • 7.3.3. Global Terbinafine Hydrochloride Drug by: Duration of therapy (Volume)
        • 7.3.3.1. Fingernail onychomycosis
        • 7.3.3.2. Toenail onychomycosis
      • 7.3.4. Global Terbinafine Hydrochloride Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Terbinafine Hydrochloride Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Terbinafine Hydrochloride Drug: by Application(USD Million)
  • Table 2. Terbinafine Hydrochloride Drug Athlete's Foot , by Region USD Million (2015-2020)
  • Table 3. Terbinafine Hydrochloride Drug Jock Itch , by Region USD Million (2015-2020)
  • Table 4. Terbinafine Hydrochloride Drug Ringworm , by Region USD Million (2015-2020)
  • Table 5. Terbinafine Hydrochloride Drug Others , by Region USD Million (2015-2020)
  • Table 6. Terbinafine Hydrochloride Drug: by Route of Administration(USD Million)
  • Table 7. Terbinafine Hydrochloride Drug Topical , by Region USD Million (2015-2020)
  • Table 8. Terbinafine Hydrochloride Drug Oral , by Region USD Million (2015-2020)
  • Table 9. Terbinafine Hydrochloride Drug: by Duration of therapy(USD Million)
  • Table 10. Terbinafine Hydrochloride Drug Fingernail onychomycosis , by Region USD Million (2015-2020)
  • Table 11. Terbinafine Hydrochloride Drug Toenail onychomycosis , by Region USD Million (2015-2020)
  • Table 12. South America Terbinafine Hydrochloride Drug, by Country USD Million (2015-2020)
  • Table 13. South America Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 14. South America Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 15. South America Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 16. South America Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 17. Brazil Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 18. Brazil Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 19. Brazil Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 20. Brazil Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 21. Argentina Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 22. Argentina Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 23. Argentina Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 24. Argentina Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 25. Rest of South America Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 27. Rest of South America Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 28. Rest of South America Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 29. Asia Pacific Terbinafine Hydrochloride Drug, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 32. Asia Pacific Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 33. Asia Pacific Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 34. China Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 35. China Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 36. China Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 37. China Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 38. Japan Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 39. Japan Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 40. Japan Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 41. Japan Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 42. India Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 43. India Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 44. India Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 45. India Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 46. South Korea Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 47. South Korea Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 48. South Korea Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 49. South Korea Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 50. Taiwan Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 51. Taiwan Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 52. Taiwan Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 53. Taiwan Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 54. Australia Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 55. Australia Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 56. Australia Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 57. Australia Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 62. Europe Terbinafine Hydrochloride Drug, by Country USD Million (2015-2020)
  • Table 63. Europe Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 64. Europe Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 65. Europe Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 66. Europe Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 67. Germany Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 68. Germany Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 69. Germany Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 70. Germany Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 71. France Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 72. France Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 73. France Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 74. France Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 75. Italy Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 76. Italy Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 77. Italy Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 78. Italy Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 79. United Kingdom Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 80. United Kingdom Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 81. United Kingdom Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 82. United Kingdom Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 83. Netherlands Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 84. Netherlands Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 85. Netherlands Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 86. Netherlands Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 87. Rest of Europe Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 88. Rest of Europe Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 89. Rest of Europe Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 90. Rest of Europe Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 91. MEA Terbinafine Hydrochloride Drug, by Country USD Million (2015-2020)
  • Table 92. MEA Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 93. MEA Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 94. MEA Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 95. MEA Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 96. Middle East Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 97. Middle East Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 98. Middle East Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 99. Middle East Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 100. Africa Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 101. Africa Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 102. Africa Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 103. Africa Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 104. North America Terbinafine Hydrochloride Drug, by Country USD Million (2015-2020)
  • Table 105. North America Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 106. North America Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 107. North America Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 108. North America Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 109. United States Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 110. United States Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 111. United States Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 112. United States Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 113. Canada Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 114. Canada Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 115. Canada Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 116. Canada Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 117. Mexico Terbinafine Hydrochloride Drug, by Application USD Million (2015-2020)
  • Table 118. Mexico Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2015-2020)
  • Table 119. Mexico Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2015-2020)
  • Table 120. Mexico Terbinafine Hydrochloride Drug, by Patient USD Million (2015-2020)
  • Table 121. Terbinafine Hydrochloride Drug Sales: by Application(K Tons)
  • Table 122. Terbinafine Hydrochloride Drug Sales Athlete's Foot , by Region K Tons (2015-2020)
  • Table 123. Terbinafine Hydrochloride Drug Sales Jock Itch , by Region K Tons (2015-2020)
  • Table 124. Terbinafine Hydrochloride Drug Sales Ringworm , by Region K Tons (2015-2020)
  • Table 125. Terbinafine Hydrochloride Drug Sales Others , by Region K Tons (2015-2020)
  • Table 126. Terbinafine Hydrochloride Drug Sales: by Route of Administration(K Tons)
  • Table 127. Terbinafine Hydrochloride Drug Sales Topical , by Region K Tons (2015-2020)
  • Table 128. Terbinafine Hydrochloride Drug Sales Oral , by Region K Tons (2015-2020)
  • Table 129. Terbinafine Hydrochloride Drug Sales: by Duration of therapy(K Tons)
  • Table 130. Terbinafine Hydrochloride Drug Sales Fingernail onychomycosis , by Region K Tons (2015-2020)
  • Table 131. Terbinafine Hydrochloride Drug Sales Toenail onychomycosis , by Region K Tons (2015-2020)
  • Table 132. South America Terbinafine Hydrochloride Drug Sales, by Country K Tons (2015-2020)
  • Table 133. South America Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 134. South America Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 135. South America Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 136. South America Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 137. Brazil Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 138. Brazil Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 139. Brazil Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 140. Brazil Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 141. Argentina Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 142. Argentina Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 143. Argentina Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 144. Argentina Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 145. Rest of South America Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 146. Rest of South America Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 147. Rest of South America Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 148. Rest of South America Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 149. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Country K Tons (2015-2020)
  • Table 150. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 151. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 152. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 153. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 154. China Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 155. China Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 156. China Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 157. China Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 158. Japan Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 159. Japan Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 160. Japan Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 161. Japan Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 162. India Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 163. India Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 164. India Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 165. India Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 166. South Korea Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 167. South Korea Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 168. South Korea Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 169. South Korea Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 170. Taiwan Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 171. Taiwan Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 172. Taiwan Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 173. Taiwan Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 174. Australia Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 175. Australia Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 176. Australia Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 177. Australia Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 178. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 179. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 180. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 181. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 182. Europe Terbinafine Hydrochloride Drug Sales, by Country K Tons (2015-2020)
  • Table 183. Europe Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 184. Europe Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 185. Europe Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 186. Europe Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 187. Germany Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 188. Germany Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 189. Germany Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 190. Germany Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 191. France Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 192. France Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 193. France Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 194. France Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 195. Italy Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 196. Italy Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 197. Italy Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 198. Italy Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 199. United Kingdom Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 200. United Kingdom Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 201. United Kingdom Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 202. United Kingdom Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 203. Netherlands Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 204. Netherlands Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 205. Netherlands Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 206. Netherlands Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 207. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 208. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 209. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 210. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 211. MEA Terbinafine Hydrochloride Drug Sales, by Country K Tons (2015-2020)
  • Table 212. MEA Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 213. MEA Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 214. MEA Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 215. MEA Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 216. Middle East Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 217. Middle East Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 218. Middle East Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 219. Middle East Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 220. Africa Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 221. Africa Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 222. Africa Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 223. Africa Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 224. North America Terbinafine Hydrochloride Drug Sales, by Country K Tons (2015-2020)
  • Table 225. North America Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 226. North America Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 227. North America Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 228. North America Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 229. United States Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 230. United States Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 231. United States Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 232. United States Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 233. Canada Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 234. Canada Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 235. Canada Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 236. Canada Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 237. Mexico Terbinafine Hydrochloride Drug Sales, by Application K Tons (2015-2020)
  • Table 238. Mexico Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 239. Mexico Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2015-2020)
  • Table 240. Mexico Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2015-2020)
  • Table 241. Company Basic Information, Sales Area and Its Competitors
  • Table 242. Company Basic Information, Sales Area and Its Competitors
  • Table 243. Company Basic Information, Sales Area and Its Competitors
  • Table 244. Company Basic Information, Sales Area and Its Competitors
  • Table 245. Company Basic Information, Sales Area and Its Competitors
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Terbinafine Hydrochloride Drug: by Application(USD Million)
  • Table 252. Terbinafine Hydrochloride Drug Athlete's Foot , by Region USD Million (2021-2026)
  • Table 253. Terbinafine Hydrochloride Drug Jock Itch , by Region USD Million (2021-2026)
  • Table 254. Terbinafine Hydrochloride Drug Ringworm , by Region USD Million (2021-2026)
  • Table 255. Terbinafine Hydrochloride Drug Others , by Region USD Million (2021-2026)
  • Table 256. Terbinafine Hydrochloride Drug: by Route of Administration(USD Million)
  • Table 257. Terbinafine Hydrochloride Drug Topical , by Region USD Million (2021-2026)
  • Table 258. Terbinafine Hydrochloride Drug Oral , by Region USD Million (2021-2026)
  • Table 259. Terbinafine Hydrochloride Drug: by Duration of therapy(USD Million)
  • Table 260. Terbinafine Hydrochloride Drug Fingernail onychomycosis , by Region USD Million (2021-2026)
  • Table 261. Terbinafine Hydrochloride Drug Toenail onychomycosis , by Region USD Million (2021-2026)
  • Table 262. South America Terbinafine Hydrochloride Drug, by Country USD Million (2021-2026)
  • Table 263. South America Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 264. South America Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 265. South America Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 266. South America Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 267. Brazil Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 268. Brazil Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 269. Brazil Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 270. Brazil Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 271. Argentina Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 272. Argentina Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 273. Argentina Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 274. Argentina Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 275. Rest of South America Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 276. Rest of South America Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 277. Rest of South America Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 278. Rest of South America Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 279. Asia Pacific Terbinafine Hydrochloride Drug, by Country USD Million (2021-2026)
  • Table 280. Asia Pacific Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 281. Asia Pacific Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 282. Asia Pacific Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 283. Asia Pacific Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 284. China Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 285. China Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 286. China Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 287. China Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 288. Japan Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 289. Japan Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 290. Japan Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 291. Japan Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 292. India Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 293. India Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 294. India Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 295. India Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 296. South Korea Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 297. South Korea Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 298. South Korea Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 299. South Korea Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 300. Taiwan Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 301. Taiwan Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 302. Taiwan Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 303. Taiwan Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 304. Australia Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 305. Australia Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 306. Australia Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 307. Australia Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 308. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 309. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 310. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 311. Rest of Asia-Pacific Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 312. Europe Terbinafine Hydrochloride Drug, by Country USD Million (2021-2026)
  • Table 313. Europe Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 314. Europe Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 315. Europe Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 316. Europe Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 317. Germany Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 318. Germany Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 319. Germany Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 320. Germany Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 321. France Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 322. France Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 323. France Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 324. France Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 325. Italy Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 326. Italy Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 327. Italy Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 328. Italy Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 329. United Kingdom Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 330. United Kingdom Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 331. United Kingdom Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 332. United Kingdom Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 333. Netherlands Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 334. Netherlands Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 335. Netherlands Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 336. Netherlands Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 337. Rest of Europe Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 338. Rest of Europe Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 339. Rest of Europe Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 340. Rest of Europe Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 341. MEA Terbinafine Hydrochloride Drug, by Country USD Million (2021-2026)
  • Table 342. MEA Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 343. MEA Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 344. MEA Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 345. MEA Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 346. Middle East Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 347. Middle East Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 348. Middle East Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 349. Middle East Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 350. Africa Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 351. Africa Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 352. Africa Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 353. Africa Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 354. North America Terbinafine Hydrochloride Drug, by Country USD Million (2021-2026)
  • Table 355. North America Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 356. North America Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 357. North America Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 358. North America Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 359. United States Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 360. United States Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 361. United States Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 362. United States Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 363. Canada Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 364. Canada Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 365. Canada Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 366. Canada Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 367. Mexico Terbinafine Hydrochloride Drug, by Application USD Million (2021-2026)
  • Table 368. Mexico Terbinafine Hydrochloride Drug, by Route of Administration USD Million (2021-2026)
  • Table 369. Mexico Terbinafine Hydrochloride Drug, by Duration of therapy USD Million (2021-2026)
  • Table 370. Mexico Terbinafine Hydrochloride Drug, by Patient USD Million (2021-2026)
  • Table 371. Terbinafine Hydrochloride Drug Sales: by Application(K Tons)
  • Table 372. Terbinafine Hydrochloride Drug Sales Athlete's Foot , by Region K Tons (2021-2026)
  • Table 373. Terbinafine Hydrochloride Drug Sales Jock Itch , by Region K Tons (2021-2026)
  • Table 374. Terbinafine Hydrochloride Drug Sales Ringworm , by Region K Tons (2021-2026)
  • Table 375. Terbinafine Hydrochloride Drug Sales Others , by Region K Tons (2021-2026)
  • Table 376. Terbinafine Hydrochloride Drug Sales: by Route of Administration(K Tons)
  • Table 377. Terbinafine Hydrochloride Drug Sales Topical , by Region K Tons (2021-2026)
  • Table 378. Terbinafine Hydrochloride Drug Sales Oral , by Region K Tons (2021-2026)
  • Table 379. Terbinafine Hydrochloride Drug Sales: by Duration of therapy(K Tons)
  • Table 380. Terbinafine Hydrochloride Drug Sales Fingernail onychomycosis , by Region K Tons (2021-2026)
  • Table 381. Terbinafine Hydrochloride Drug Sales Toenail onychomycosis , by Region K Tons (2021-2026)
  • Table 382. South America Terbinafine Hydrochloride Drug Sales, by Country K Tons (2021-2026)
  • Table 383. South America Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 384. South America Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 385. South America Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 386. South America Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 387. Brazil Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 388. Brazil Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 389. Brazil Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 390. Brazil Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 391. Argentina Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 392. Argentina Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 393. Argentina Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 394. Argentina Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 395. Rest of South America Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 396. Rest of South America Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 397. Rest of South America Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 398. Rest of South America Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 399. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Country K Tons (2021-2026)
  • Table 400. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 401. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 402. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 403. Asia Pacific Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 404. China Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 405. China Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 406. China Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 407. China Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 408. Japan Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 409. Japan Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 410. Japan Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 411. Japan Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 412. India Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 413. India Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 414. India Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 415. India Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 416. South Korea Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 417. South Korea Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 418. South Korea Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 419. South Korea Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 420. Taiwan Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 421. Taiwan Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 422. Taiwan Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 423. Taiwan Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 424. Australia Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 425. Australia Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 426. Australia Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 427. Australia Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 428. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 429. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 430. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 431. Rest of Asia-Pacific Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 432. Europe Terbinafine Hydrochloride Drug Sales, by Country K Tons (2021-2026)
  • Table 433. Europe Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 434. Europe Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 435. Europe Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 436. Europe Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 437. Germany Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 438. Germany Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 439. Germany Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 440. Germany Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 441. France Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 442. France Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 443. France Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 444. France Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 445. Italy Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 446. Italy Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 447. Italy Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 448. Italy Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 449. United Kingdom Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 450. United Kingdom Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 451. United Kingdom Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 452. United Kingdom Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 453. Netherlands Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 454. Netherlands Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 455. Netherlands Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 456. Netherlands Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 457. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 458. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 459. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 460. Rest of Europe Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 461. MEA Terbinafine Hydrochloride Drug Sales, by Country K Tons (2021-2026)
  • Table 462. MEA Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 463. MEA Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 464. MEA Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 465. MEA Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 466. Middle East Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 467. Middle East Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 468. Middle East Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 469. Middle East Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 470. Africa Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 471. Africa Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 472. Africa Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 473. Africa Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 474. North America Terbinafine Hydrochloride Drug Sales, by Country K Tons (2021-2026)
  • Table 475. North America Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 476. North America Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 477. North America Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 478. North America Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 479. United States Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 480. United States Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 481. United States Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 482. United States Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 483. Canada Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 484. Canada Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 485. Canada Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 486. Canada Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 487. Mexico Terbinafine Hydrochloride Drug Sales, by Application K Tons (2021-2026)
  • Table 488. Mexico Terbinafine Hydrochloride Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 489. Mexico Terbinafine Hydrochloride Drug Sales, by Duration of therapy K Tons (2021-2026)
  • Table 490. Mexico Terbinafine Hydrochloride Drug Sales, by Patient K Tons (2021-2026)
  • Table 491. Research Programs/Design for This Report
  • Table 492. Key Data Information from Secondary Sources
  • Table 493. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Terbinafine Hydrochloride Drug: by Application USD Million (2015-2020)
  • Figure 5. Global Terbinafine Hydrochloride Drug: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Terbinafine Hydrochloride Drug: by Duration of therapy USD Million (2015-2020)
  • Figure 7. South America Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 8. Asia Pacific Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 9. Europe Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 10. MEA Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 11. North America Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 12. Global Terbinafine Hydrochloride Drug: by Application K Tons (2015-2020)
  • Figure 13. Global Terbinafine Hydrochloride Drug: by Route of Administration K Tons (2015-2020)
  • Figure 14. Global Terbinafine Hydrochloride Drug: by Duration of therapy K Tons (2015-2020)
  • Figure 15. South America Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 16. Asia Pacific Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 17. Europe Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 18. MEA Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 19. North America Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 20. Global Terbinafine Hydrochloride Drug share by Players 2020 (%)
  • Figure 21. Global Terbinafine Hydrochloride Drug share by Players (Top 3) 2020(%)
  • Figure 22. Global Terbinafine Hydrochloride Drug share by Players (Top 5) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 26. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 28. TEVA (Israel) Revenue, Net Income and Gross profit
  • Figure 29. TEVA (Israel) Revenue: by Geography 2020
  • Figure 30. Dr. Reddy's Laboratories(India) Revenue, Net Income and Gross profit
  • Figure 31. Dr. Reddy's Laboratories(India) Revenue: by Geography 2020
  • Figure 32. CIPLA LTD (India) Revenue, Net Income and Gross profit
  • Figure 33. CIPLA LTD (India) Revenue: by Geography 2020
  • Figure 34. Quimica Sintetica S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 35. Quimica Sintetica S.A. (Spain) Revenue: by Geography 2020
  • Figure 36. Dipharma (United States) Revenue, Net Income and Gross profit
  • Figure 37. Dipharma (United States) Revenue: by Geography 2020
  • Figure 38. InvaGen Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 39. InvaGen Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 40. Breckenridge Pharmaceutical(United States) Revenue, Net Income and Gross profit
  • Figure 41. Breckenridge Pharmaceutical(United States) Revenue: by Geography 2020
  • Figure 42. Harris Pharmaceutical(United States) Revenue, Net Income and Gross profit
  • Figure 43. Harris Pharmaceutical(United States) Revenue: by Geography 2020
  • Figure 44. Global Terbinafine Hydrochloride Drug: by Application USD Million (2021-2026)
  • Figure 45. Global Terbinafine Hydrochloride Drug: by Route of Administration USD Million (2021-2026)
  • Figure 46. Global Terbinafine Hydrochloride Drug: by Duration of therapy USD Million (2021-2026)
  • Figure 47. South America Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 48. Asia Pacific Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 49. Europe Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 50. MEA Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 51. North America Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 52. Global Terbinafine Hydrochloride Drug: by Application K Tons (2021-2026)
  • Figure 53. Global Terbinafine Hydrochloride Drug: by Route of Administration K Tons (2021-2026)
  • Figure 54. Global Terbinafine Hydrochloride Drug: by Duration of therapy K Tons (2021-2026)
  • Figure 55. South America Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 56. Asia Pacific Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 57. Europe Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 58. MEA Terbinafine Hydrochloride Drug Share (%), by Country
  • Figure 59. North America Terbinafine Hydrochloride Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis (Switzerland)
  • GSK (United Kingdom)
  • TEVA (Israel)
  • Dr. Reddy's Laboratories(India)
  • CIPLA LTD (India)
  • Quimica Sintetica S.A. (Spain)
  • Dipharma (United States)
  • InvaGen Pharmaceuticals (United States)
  • Breckenridge Pharmaceutical(United States)
  • Harris Pharmaceutical(United States)
Additional players considered in the study are as follows:
Glenmark (India) , Orchid Healthcare (India) , APOTEX (Canada) , Jilin Wantong Group (China)
Select User Access Type

Key Highlights of Report


Sep 2021 221 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Terbinafine Hydrochloride Drug Quantitative research analysis
Global Terbinafine Hydrochloride Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing sports and event worldwide " is seen as one of major growth factors of Terbinafine Hydrochloride Drug Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Terbinafine Hydrochloride Drug Market in coming years.

Know More About Global Terbinafine Hydrochloride Drug Report?

Have a Query? Click Here

Other Related Reports

Specialty Supplements Comprehensive Study by Application (Skin Care, Hair Care, Nutritional Deficiency, Cardiac Care, Mind Care, Others), Sales (Online, Offline), Form (Liquid, Powder, Capsule), Ingr...
$ 3450
Commercial Pharmaceutical Analytics Comprehensive Study by Type (Descriptive analytics, Predictive analytics, Prescriptive analytics), Application (Research & Development, Marketing & Sales, Supply C...
$ 3450
Jojoba Oil Comprehensive Study by Type (Unrefined, Refined), Application (Cosmetics & Personal care, Pharmaceutical, Industrial, Others), Distribution Channel (Hypermarkets/Supermarkets, Convenience ...
$ 3350
Pharmaceutical Manufacturing Comprehensive Study by Type (Continuous, Batch processing), Prescription (Prescription Based Medicines, OTC (Over the Counter) Medicines), End Users (Neonates and Pediatr...
$ 3750
Controlled Release Drug Delivery Comprehensive Study by Type (Inhalers, Injectable, Others), Application (Hospitals & Clinics, Research Organisations), Route of Administration (Oral, Transdermal, Oth...
$ 3450
Medical Penicillin Comprehensive Study by Type (Natural Penicillins (Benzylpenicillin, Phenoxymethylpenicillin), Penicillinase Resistant, Extended Spectrum, Anti-Pseudomonal), Application (Respirator...
$ 3750